Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) have been given an average broker rating score of 3.00 (Hold) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold rating. ProNAi Therapeutics’ rating score has declined by 20% in the last 90 days as a result of various analysts’ ratings changes.
Analysts have set a 12-month consensus price target of $2.50 for the company and are forecasting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also given ProNAi Therapeutics an industry rank of 109 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research cut ProNAi Therapeutics from a “buy” rating to a “sell” rating in a report on Monday, August 8th.
Shares of ProNAi Therapeutics (NASDAQ:DNAI) opened at 1.75 on Thursday. The company has a 50-day moving average price of $1.84 and a 200 day moving average price of $3.23. ProNAi Therapeutics has a one year low of $1.75 and a one year high of $20.85. The company’s market capitalization is $53.07 million.
ProNAi Therapeutics (NASDAQ:DNAI) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.05. Equities analysts anticipate that ProNAi Therapeutics will post ($1.32) EPS for the current year.
Several institutional investors have recently made changes to their positions in the stock. Deerfield Management Co. boosted its position in shares of ProNAi Therapeutics by 67.6% in the first quarter. Deerfield Management Co. now owns 3,001,302 shares of the company’s stock worth $20,229,000 after buying an additional 1,210,047 shares in the last quarter. Vivo Capital LLC purchased a new position in shares of ProNAi Therapeutics during the first quarter worth $16,434,000. Renaissance Technologies LLC boosted its position in shares of ProNAi Therapeutics by 16.2% in the first quarter. Renaissance Technologies LLC now owns 45,300 shares of the company’s stock worth $305,000 after buying an additional 6,300 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of ProNAi Therapeutics by 4.6% in the second quarter. PNC Financial Services Group Inc. now owns 601,092 shares of the company’s stock worth $1,197,000 after buying an additional 26,226 shares in the last quarter. Finally, Greenleaf Trust boosted its position in shares of ProNAi Therapeutics by 7.8% in the second quarter. Greenleaf Trust now owns 207,450 shares of the company’s stock worth $413,000 after buying an additional 14,956 shares in the last quarter. 35.25% of the stock is currently owned by institutional investors.
About ProNAi Therapeutics
ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.